361 Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

361 Capital’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-70,817	Closed	-$1.42M	–	439
2018 Q3	$1.42M	Buy	+70,817	New	+$1.66M	0.31%	195

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

361 Capital's ADMS Position: Q4 2018 in Review

361 Capital sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 70,817 shares — an estimated $1.42M sold.

361 Capital first reported a position in ADMS in Q3 2018 and held it in 1 quarter. The position peaked at $1.42M in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

361 Capital reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
361 Capital sold 70,817 Adamas Pharmaceuticals shares in Q4 2018, an estimated $1.42M.
361 Capital first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 1 quarter.
361 Capital's Adamas Pharmaceuticals position peaked at $1.42M in Q3 2018.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on 361 Capital's 13F filing for Q4 2018, filed 8 Feb 2019.